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Cytoprotection of kidney epithelial cells by compounds that target
amino acid gated chloride channels. Glycine, strychnine and certain
chloride channel blockers were reported to protect cells against lethal cell
injury. These effects have been attributed to interactions with membrane
proteins related to CNS glycine gated chloride channel receptors. We have
investigated the pharmacology of these actions. Madin-Darby canine
kidney (MDCK) epithelial cells were depleted of adenosine triphosphate
(ATP) by incubation in glucose free medium containing a mitochondrial
uncoupler. Medium Ca2 was adjusted to 100 nM in the presence of an
ionophore such that intracellular Ca2 did not increase, and Ca2-related
injury mechanisms were inhibited. This permitted more sensitive quanti-
tation of protection against cell injury attributable to glycine or other
agents whose actions might be related to those of the amino acid. Two
classes of compounds showed cytoprotective activity in this system: (1)
ligands at chloride channel receptors, such as glycine, strychnine and
avermectin Bla; (2) chloride channel blockers, including cyanotriphenyl-
boron and niflumic acid, both of which arc known to bind to channel
domains of CNS glycine receptors. Morphological and functional studies
showed that the compounds preserved plasma membrane integrity, but
permitted cell swelling. Substitution of medium chloride by gluconate, or
chloride salts by sucrose, did not substantially modify lethal damage or its
prevention by glycine or other drugs. The compounds did not modify ATP
declines. At least for some compounds, cytoprotection appeared to be specific
to structural features on the molecules. These observations are consistent
with the hypothesis that a plasma membrane protein related to glycine-gated
chloride channel receptors plays a significant role in cell injury, but indicate
that the mechanisms of injury and protection by compounds active in this
system are not related to chloride fluxes.
Glycine and related amino acids protect cells from the lethal
effects of ATP depletion without modifying metabolism [1—10].
Strychnine has similar actions [11, 12]. Overlaps between struc-
ture-activity relationships of amino acids as agonists at ligand-
gated chloride channel receptors [13], and as cytoprotective
agents [2—4], have suggested that amino acids may protect cells by
low affinity interactions with a protein that is related to CNS
glycine receptors [3, 4]. It has been suggested that strychnine
protects cells by a similar mechanism [14, 15]. According to this
view, ATP depletion causes lethal chloride influx through the
receptors, which is prevented by glycine and strychnine [14].
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Reports that chloride channel blockers are also cytoprotective [14,
16] would seem to support this view. However, this hypothesis is
inconsistent with actions of glycine and strychnine on glycine
receptors; glycine stimulates chloride currents, whereas strychnine
is an antagonist [131.
We investigated possible cytoprotective effects of two broad
classes of compounds: agents with activities at amino acid gated
chloride channels, and several species of chloride channel block-
ers. A premise for these experiments was that the protective
actions of these compounds, if any, might be directed at mecha-
nisms targeted by glycine. Consequently, we studied their effects
in the context of membrane damage that is stringently dependent
on glycine deficiency, is completely retarded by exogenous amino
acid, and is uncomplicated by glycine-insensitive structural disrup-
tion caused by increased intracellular ionized (or "free") calcium
(Caf). This was accomplished by using a model of injury to MDCK
cells described recently. Cells are incubated with a mitochondrial
uncoupler to deplete them of ATP in medium with Ca2 adjusted
to 100 nM using EGTA, with a calcium ionophore, so that Caf is
clamped at 100 nM [17]. Because Caf cannot increase, injury
caused by excessive Ca2 is avoided, but damage that is prevented
by glycine is fully expressed [17].
In the present experiments, the calcium clamping technique was
particularly important for detecting pharmacological effects of
compounds whose actions may be related to those of glycine, but
weaker than those of the amino acid. Results using this model
show that several compounds that bind to strychnine-sensitive
glycine receptors, or block chloride channels, also prevent mem-
brane damage in ATP depleted cells. However, isosmotic replace-
ment of extracellular chloride by gluconate, or chloride salts by
sucrose, did not significantly modify the parameters of injury or
protection, suggesting that the underlying mechanisms are unre-
lated to membrane fluxes of chloride.
Methods
Experimental design
MDCK cells were grown as described [17], plated at 400,000 per
35 mm dish and used after overnight culture. Cells were incubated
in glucose free Krebs-Ringer bicarbonate solution (KRB) contain-
ing (in mM) 115 NaCI, 3.5 KC1, 25 NaHCO3, 1 KH2PO4, 1.25
CaC12, and 1 MgSO4, gassed with 95% air, 5% CO2. Carbonyl
cyanide-m-chlorophenyl hydrazone (CCCP), an uncoupler of
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Fig. 1. MDCK cells were incubated in KRB containing 100 nM Ca2 with 5 pM ionomycin and 15 p.M CCCP and no further additions (NFA) or various
concentrations of (A) glycine, (B) avermectin B1a, or (C) stiychnine (drug concentrations are indicated in millimolar). Symbols in (A) are: (0) NFA; (LII)
0.10; (Y) 0.25; (V) 1.0; (S) 5.0. Symbols in (B) are: (0) NFA; (LI) 0.0001; (Y) 0.001; (V) 0.01; (•) 0.10. Symbols in (C) are: (0) NFA; (LI) 0.1; (V)
0.25; (7) 0.5; (•) 1.0. Free LDH in the medium was measured at 60, 120 and 180 minutes (N = 5). At two hours, glycine was significantly protective
in concentrations down to 0.1 mi (100 JLM), but protection at three hours required concentrations of 0.25 m or higher. Avermectin was protective in
concentrations of 0.01 and 0.1 mro (10 and 100 M) at both time periods. With strychnine, 0.5 or 1 mivi drug was required to achieve significant decrease
of LDH release relative to the NFA group. On a molar basis, avermectin was most protective at all time periods. Error bars are not shown for clarity.
oxidative phosphorylation, and ionomycin, a Ca2 ionophore,
were added as l000x solutions in ethanol at final concentrations
of 15 M and 5 j.LM. The medium contained 2.25 mivi EGTAso that
Ca2 was buffered to 100 nrvi [8]. Incubations were at 37°C under
6% CO2 in air; pH of the incubation medium was between 7.43 to
7.45. Drugs were added to the media as box stock solutions in
DMSO, ethyl alcohol or water. Controls received vehicle alone. In
some experiments, chloride ions or chloride salts in the incubation
medium were isosmotically replaced by gluconate or sucrose,
respectively. To replace chloride ions, Na gluconate and K
gluconate were substituted for NaCI and KC1, and CaSO4 was
used instead of CaC12. Medium bicarbonate content was increased
to 26 m to keep pH at 7.43-7.45. To replace chloride salts, NaCl
and KCI were replaced isosmotically by sucrose, and CaCl2 was
replaced by Ca acetate.
Methods
Lactate dehydrogenase (LDH), protein and ATP were mea-
sured as described [8, 9, 18]. Cells were fixed in glutaraldehyde
and osmium tetroxide, and processed for electron microscopy by
standard techniques. Plasma membrane permeability to fluores-
cein (molecular wt 332) and propidium iodide (P1, molecular wt
668) was assessed [19]. Experimental medium was replaced with
0.02 M phosphate buffered saline (PBS) containing 18.75 p.g/ml
fluorescein diacetate (FDA) and 2 p.g/ml P1. After three minutes,
cells were transferred to PBS, and photographed using epifluo-
rescence optics. Fluorescein and P1 were viewed simultaneously
using a 420 to 490 nm excitation filter, 505 nm beam splitter and
520 nm long pass barrier filter.
Reagents
Avermectin Bla and derivatives were gifts from Drs. Sam
Cifelli and Michael Fisher, Merck Research Laboratories (Rah-
way, NJ, USA). Cyanotriphenylboron sodium salt was a gift from
Dr. Heinrich Betz, Max Planck Institute for Brain Research
(Frankfurt, Germany). Indanyloxyacetic acid 94 (IAA), 5-nitro-2-
(3-phenylpropylamino) benzoic acid (NPPB), and N-phenylan-
thranilic acid (diphenylamine-2-carboxylic acid, DPC) were from
Research Biochemicals International (Natick, MA, USA). All
other chemicals were from Sigma Chemicals Co. (St. Louis, MO,
USA).
Statistics
Values are means SE. Data were analyzed by analysis of
variance for repeated measure designs and the Neuman-Keuls
test for multiple comparisons. P < 0.05 or lower in a two tailed
comparison was considered significant.
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Fig. 2. MDCK cells were incubated for two hours(A) or three hours (B) in 100 nii Ca2 medium
with ionomycin and CCCP, with vehicle
alone (VEH), 2 mM glycine (GLY),
cyanotriphenylboron sodium salt (CTB,
0.01, 0.025, 0.05 or 0.1 mM), or
triphenylmethylphosphonium bromide (TPM,
0.01, 0.025, 0.05 or 0.1 mM). Symbols are: (LII)
0.01 mM, () 0.025 mi, () 0.05 mM, (Li) 0.1
mM. Time controls (TC) were incubated
without ionomycin or CCCP in the presence or
absence of 0.1 mM CTB or TPM. There was
dose dependent inhibition of LDH release by
CTB, significant for all concentrations 0.025 mwi
and higher. TPM was ineffective. (N = 4).
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Fig. 3. Electron microscopy of injured and protected MDCK cells incubated for three hours in 100 nie Ca2 medium without further additions (a), with
ionomycin and CCCP alone (b) and with ionomycin and CCCP in the presence of 5 mM glycine (c), 1 mM st,ychnine (d), 0.1 mM avermectin Bla (e) or 0.1
mM cyanotriphenylboron sodium salt (f). Compared to the time control in (a), cells with ionomycin and CCCP and no further additions (b) show swelling
of cell bodies and all organelles including the nuclear envelope. The cytoplasm is vacant, with noticeable lack of electron dense material (asterisk),
particularly in large, swollen areas underlying the plasma membrane (arrow). Cells with ionomycin and CCCP, and either glycine, strychnine, avermectin
or cyanotriphenylboron (c—f) also exhibit severe swelling of all organelles and cytoplasmic swelling forming blebs, but the cytoplasmic density is greater,
and they retain cytosolic protein, visible as electron dense granular material shown strikingly well within swollen blebs (asterisks), limited by the plasma
membranes (arrows). LDH release assessed in the medium prior to fixation for EM, expressed as percentage of total LDH in parallel dishes were as
follows: time control (a), 7%; ionomycin and CCCP (I+C) with no further additions (b), 100%; I+C with glycine (c), 5%; I+C with strychnine (d), 7%;
I+C with avermectin (e), 23%; I+C with cyanotriphenylboron (f), 5%. Magnifications are X3200 for a, b, d and f, and x5000 for c and e.
Results
Incubation of MDCK cells with ionomycin and CCCP in 100 nM
Ca2 medium with no further additions led to progressive loss of
plasma membrane integrity measured as LDH release (Fig. 1).
Compounds with activity at strychnine-sensitive CNS glycine
receptors prevent leakage of LDH from A TP depleted MDCK cells
Avermectin Bla is an agonist at several types of ligand gated
chloride channels in lower animals but also binds to GABAA and
glycine receptor chloride channels in mammalian CNS [13, 20—
23]. Strychnine is an antagonist of inhibitory glycine receptors
[13]. Avermectin Bla and strychnine hydrochloride were included
in the incubation medium and their effects on cell injury com-
pared to that of glycine (Fig. 1). Concentrations of 0.5 and 1.0mM
strychnine strongly inhibited LDH release. Avermectin Bla had
the same effect in much lower concentrations of 0.01 and 0.1 mM.
In comparison, glycine was only moderately effective at 0.1 mM,
with much stronger protection being observed in the range of 0.25
to 5 m (Fig. 1). Cyanotriphenylboron, which blocks glycine and
GABA gated chloride channels [24], potently inhibited the release
of LDH (Fig. 2 A, B). Strong inhibitory effects were observed
using concentrations as low as 0.025 m, although higher concen-
trations were required to maintain protection during longer
durations of incubation. As noted earlier, much higher concen-
trations of glycine were required to obtain equivalent protective
effects (Fig. 1).
Structural correlates of LDH release or its prevention
By electron microscopy, there was marked swelling of cells and
organelles at three hours, with large empty spaces in the cyto-
plasm (Fig. 3B). Cells with glycine, strychnine, avermectin or
cyanotriphenyboron were similarly swollen, but maintained
denser cytoplasmic texture, and contained granular electron dense
material even in the most swollen areas, consistent with retention
of cytosolic protein by plasma membranes (Fig. 3 C-F). Plasma
membranes were separated from the cytoplasm, forming blebs
containing granular electron dense material (Fig. 3 C-F). These
changes were absent in vehicle controls (Fig. 3A), and untreated
cells (not shown).
Following exposure to FDA and Pt, control cells showed green,
but no red fluorescence, indicating that plasma membranes were
impermeable to fluorescein and P1 (Fig. 4 A, B). The large
majority of cells incubated with CCCP and ionomycin alone for
three hours showed red, but no green fluorescence; the rare
exceptions fluoresced green (Fig. 4C). In contrast, the vast
majority of cells incubated with optimal concentrations of glycine,
strychnine or cyanotriphenylboron were green (Fig. 4 D, E, H).
Time Control
I+C, Vehicle control
I+C, glycine 5 mM
I+C, Avermectin B1a (AVM)
I+C, 22,23-dihydro AVM (Ivermectin) (A)
I+C, 22,23-dihydro AVM-4"-O-phosphate (B)
I+C, Avermectin B2a (C)
I+C, AVM-4"-O-phosphate (D)
I+C, 22,23-dihydro AVM aglycone (E)
I+C, 22,23-dihydro AVM monosaccharide (F)
I+C, AVM monosaccharide (G)
I+C, AVM-5-ketone (H)
I+C, 2,3,8,9,10,11,22,23-octahydro-AVM (I)
I+C, 13-deoxy-AVM aglycone (J)
I+C, 13-deoxy-22,23-dihydro AVM aglycone (K)
I+C, Emamectin (MK 244) (L)
I±C, 13-0-methoxymethylene AVM (M)
H-C, 13-Epi-O-methoxy ethoxy methoxy-H2 AVM (N)
3±188 2
2 ia
55 7'I65 290 488 287 3
78 3
70 288 581 585 3
36 6"
36 8'
36 6"
15 7b
43 15"
MDCK cells were incubated in KRB with 100 nM Ca containing
ionomycin and CCCP (I+C), and either vehicle alone (DMSO), Aver-
mectin B1a, or an Avermectin analog (compounds A—N) for 3 hours. A
concentration of drug that was submaximally protective for Avermectin
B1a (10 /.LM) was used, so that increased as well as decreased protection by
analogs could be detected (N = 4).
"less than all other groups except the time control
b less than all other groups except the time control, and I & C with
glycine
"less than all other groups except time control, I+C with glycine, I+C
with compound M, and I+C with AVM
d less than I + C vehicle control, and I + C with compounds B through I
"less than I+C vehicle control, and I+C with compounds B,C,D and G
Higher fractions of cells exposed to avermectin Bla showed red
fluorescence (Fig. 4F). The incidence of red and green cells
faithfully reflected the release of LDH. Thus, plasma membranes
of protected cells were impermeable not only to the protein LDH
(molecular wt 136,000), but also to the small molecules fluores-
cein (molecular wt 332) and propidium iodide (molecular wt 668).
Effects of compounds related to avermectin and
cyanotriphenylboron
Availability of avermectin analogs permitted investigation of
the structural specificity of cytoprotection by avermectin Bla.
Modifications of avermectin structure result in alterations of
binding affinity at C. elegans muscle glutamate-gated chloride
channels and increase or decrease of vermicidal, insecticidal or
miticidal activities of avermectins [20, 21]. Cells were injured in
the presence of vehicle alone, or an avermectin analog for three
hours. A concentration of drug that was submaximally protective
Table 1. Effects of Avermectin analogs on cell injury
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Fig. 5. MDCK cells were incubated for three
hours in 100 nM Ca2 medium with ionomycin
and CCCP, with vehicle alone (VEH), glycine
(GLY, 5 mM or 0.1 mM), or different
concentrations (0.001 mAl, 0.01 msi, 0.1 mM) of
avermectin B1a (A VM), 2,3,8,9,10,11,22,23-
octahydro-AVM (OCT) or 13-0-methoxy-
methylene A VM (MOM). Whereas OCT was
inactive, both AVM and MOM protected
significantly at 10 jM and 100
.LM, and MOM
was more effective than AVM at both
concentrations. TC-Time Control without
ionomycin or CCCP (N = 4). Symbols are: (LII)
0.001 mM, () 0.01 mM, () 0.1 mM.
Fig. 6. MDCK cells were incubated in 100 nM
Ca2 medium with no further additions (time
control, TC), or containing ionomycin and CCCP
with vehicle alone (VEH), 2 miu glycine (GLY),
or different concentrations of chloride channel
blockers. Free LDH in the medium (y-axis) was
measured at two hours (N = 5). DPC-
diphenylamine-2-carboxylic acid. IAA-
indanyloxyacetic acid 94. NPPB-5-nitro-2-(3-
phenylpropylamino) benzoic acid. NIF-nifiumic
acid. Protection against LDH release by DPC,
TAA and NPPB was significant and dose
dependent. There were significant differences
between the drugs, NPPB being the most
potent. The average of two experiments done in
quadruplicate with NIF, are shown to the right
of the dotted line. They were done separately
with their own vehicle controls (VEH). There
was little variation between the quadruplicates
and the two experiments. LDH release by time
controls and injured cells protected by glycine
was similar to that shown in the left panel (not
shown). Symbols are: (LI) 0.1 mai, () 0.25 mM,() 0.5 mM, (LI:) 1.0 mM, () 2.0 mM.
for avermectin Bla (0.01 mM) was used, so that increased as well
as decreased protection by analogs could be detected. Avermectin
Bla and its 22,23-dihydro derivative Ivermectin were moderately
protective, whereas others were ineffective (Table 1). However,
five compounds, four of which lack the 2-deoxy sugar glycoside
substitutive and are modified at the 13 position, were also
effective, among which one, 13-0-methoxymethylene avermectin
Bla, was strongly cytoprotective, even better than the parent
compound (Table 1). Dose response effects for avermectin Bla,
an inactive octahydro derivative and the 13-0-methoxymethylene
analog are shown in Figure 5.
To investigate the specificity of cytoprotection by the anionic
cyanotriphenylboron, we used triphenylmethylphosphonium bro-
mide (TPMP), which has the same triphenyl structure and equiv-
alent hydrophobicity, but is positively charged [24]. TPMP blocks
cation channels of nicotiruic acetylcholine receptors, but not the
anion channels of glycine receptors [24], although the two channels
have structural similarities [25]. Conversely, cyanotriphenylboron is
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Table 2. ATP levels with chloride or gluconate
With chloride medium With gluconate medium
ATP LDH ATP LDH
TC 14.7 1.4 2 0 13.8 1.5 3 1
VEH 0.7±0.1 5±2 0.4±0.1 9±4
+GLY 0.6 0.1 3 1 0.4 0.1 4 1
+CTB 0.4 0.1 3 1 0.3 0.1 3 1
+TPM 0.9±0.3 6±2 0.4±0.1 12±5
ATP content and release of LDH from cells incubated for 1 hour in 100
nM Ca KRB containing ionomycin and CCCP in the presence of 5 mM
glycine (+GLY), 100 j.M cyanotriphenylboron sodium salt (+CTB), 100
.LM triphenylmethylphosphonium bromide (+TPM), or vehicle alone
without drugs (VEH) and in time controls without ionomycin and CCCP
(TC). Decreases of ATP relative to controls were of equal magnitude with
no significant differences between groups in chloride or gluconate media.
ATP, nmol/mg protein. LDH, percent free LDH of total (N = 4).
anion channel selective [24]. TPMP did not have protective activity,
measured as LDH release (Fig. 2), membrane permeability of
fluorescein and P1 (Fig, 4G) and structural disruption by electron
microscopy (not shown).
Protection by other chloride channel blockers
Several other chloride channel blockers were tested. These
were: Indanyloxyacetic acid 94 (IAA), N-phenylanthranilic acid
(diphenylamine-2-carboxylic acid or DPC), 5-nitro-2-(3-phenyl-
propylamino)benzoic acid (NPPB) and niflumic acid (NIF). All
four compounds were cytoprotective (Fig. 6). With IAA, NPPB
and NIF, LDH release was inhibited progressively between con-
centrations of 0.25 to 1.0 mM (Fig. 6). NPPB and NIF were the
most effective, protection being seen at concentrations down to
0.025 m in the case of NIF (not shown). On the other hand,
larger amounts of DPC were required to obtain equivalent
inhibition of LDH release (Fig. 6).
Cell A TP
Declines of ATP were equivalent and virtually complete by one
hour of incubation in all groups of protected and unprotected cells
(Tables 2 and 3).
Membrane damage is not related to medium chloride
It was suggested that chloride influx mediates cell damage by
ATP depletion [14], and chloride substitution by impermeant
anions was reported to enhance hypothermic tissue preservation
[26]. Chloride ions may modulate ligand binding at chloride
channel receptors [13, 22, 23] and compete with channel blockers
for functional sites [27]. For these reasons we examined whether
substitution of chloride ions by gluconate or chloride salts by
sucrose had any effects on injury or protection parameters.
Equivalent declines of ATP occurred during injury in the presence
or absence of test compounds, in both chloride or gluconate
media (Tables 2 and 3). LDH release from cells injured without
test compounds or in the presence of TPMP was not affected by
gluconate substitution (Fig. 7). Glycine, strychnine, cyanotriphe-
nylboron and other chloride channel blockers were equally pro-
tective in media with gluconate or chloride, but, in the case of
avermectin Bla, there was partial loss of activity (Fig. 7). The
ultrastructure of cells which had leaked LDH during incubation in
gluconate media was indistiguishable from that of equally injured
Table 3. ATP levels with chloride or gluconate
With chloride medium With gluconate medium
ATP LDH ATP LDH
TC 13.0 0.5 3 0 12.3 0.5 3 0
VEH 0.5 0.1 6 3 0.2 0.1 14 6
+GLY 0.5 0.1 3 0 0.4 0.0 3 1
+STR 0.4 0.1 3 0 0.3 0.0 3 0
+AVM 0.9 0.1 3 1 0.6 0.0 4 1
+DPC 0.4 0.1 6 1 0.2 0.0 9 2
+IAA 0.1 0.0 6 1 0.2 0.0 4 1
+NPP 0.2 0.1 1 0 0.2 0.1 2 0
+NIF 0.5 0.1 4 1 0.3 0.1 5 1
ATP content and release of LDH from cells incubated for 1 hour in 100
nM Ca KRB containing ionomycin and CCCP in the presence of 5 mM
glycine (+GLY), 1 m strychnine (+STR), 100 jsM Avermectin Bla
(+AVM), 2 mrvi diphenylamine-2-carboxylic acid (+DPC), 1 mM indany-
loxyacetic acid (+IAA), 1 mi 5-nitro-2-(3-phenylpropylamino) benzoic
acid (+NPP), 1 mat niflumic acid (+NIF) or vehicles without drugs
(VEH), and in time controls without ionomycin and CCCP (TC). De-
creases of ATP relative to controls were of equal magnitude with no
significant differences between groups in chloride or gluconate media.
ATP, nmol/mg protein. LDH, percent free LDH of total (N = 4).
cells in chloride medium (Fig. 8). On the other hand, protected
cells in gluconate media were not swollen or blebbed (shown for
glycine, Fig. 8). Cells protected by other agents had a similar
appearance (not shown).
Substantial injury occured during incubations in media contain-
ing sucrose substituted for chloride salts, in spite of the potential
benefits that the impermeant solute sucrose might be expected to
have. Cell damage under these circumstances was significantly
prevented by glycine and other test compounds. Values for
percent LDH release after three hours of incubation in 100 flM
Ca2 sucrose media were: controls, 1 0; ionomycin and CCCP,
74 1; ionomycin and CCCP with 5 mM glycine, 2 1, with 1 mM
strychnine, 3 1, with 0.1 mat avermectin Bla, 18 3, with 0.1
mM cyanotriphenylboron, 2 0, and with 1 mivi niflumic acid, 3
1(N=4).
Effects of medium Ca2 on cytoprotective activity
Cells were exposed to ionomycin and CCCP also in a "high
calcium" medium containing 1.25 mM Ca2, that is, without added
EGTA. Such cells exhibit rapid and sustained increases of Caf to
high levels [10]. High concentrations of glycine (5 mM) protect
MDCK cells under these conditions also, but the effects are
ultimately overcome by Ca2 dependent, glycine insensitive dam-
age processes [17]. In the context of current experiments using
Ca2 clamped cells, we wanted to compare relative potencies of
cytoprotective compounds under high calcium conditions also.
The results show that uncontrolled increases of Caf have a major
adverse impact on total cell damage and make impossible precise
analyses of Ca2-independent processes sensitive to, or related to
glycine.
LDH release from cells injured or protected by test compounds
(0.1, 0.5 and 1.0 mM) in 1.25 mat Ca2 medium for two hours is
shown in Table 4. With few exceptions at the 1 mM level, all
concentrations of test compounds were less effective in 1.25 mM
Ca2 medium than in 100 flM Ca2 media (Table 4; compare with
data for cells in 100 nazi Ca media, Figs. 1, 2A and 6).
Avermectin could not be tested at concentrations higher than 0.1
mM because of insolubility. At 0.1 m, protection was nearly
Fig. 7. MDCK cells were incubated for two hours
in 100 flM Ca2 medium with no further
additions (time contro4 TC), or containing
ionomycin and CCCP with vehicle (VEH), 5 m
glycine (GLY), 1 mw strychnine (STR), 0.1 mM
avermectin Bla (A I'M), 0.1 mM
cyanotnphenylboron sodium salt (CTB), 2 mM
diphenylamine-2-carboxylic acid (DPC), 1 mM
indanyloxyacetic acid 94 (IAA), 1 mw 5-nitro-2-
(3-phenyipropylamino) benzoic acid (NPP) 1 mM
niflumic acid (NIF) or 0.1 mst
triphenylmethylphosphonium bromide (TPM).
The incubations were done in the standard
medium containing chloride (LI) or medium in
which chloride was substituted by gluconate
(). Substitution by gluconate did not reduce
the extent of injury. There was a trend for
increased injury in gluconate groups with DPC
or TPM or vehicle alone with no further
additions, but this did not reach significance. In
groups with AVM, there was significantly more
injury in gluconate than in chloride medium.
Nevertheless, cells with AVM in gluconate
medium released significantly less LDH than
corresponding cells in gluconate medium
without added protective agents. In all other
groups, the extent of inhibition of LDH release
was equivalent in either chloride or gluconate
media (N = 4).
absent in 1.25 mi Ca2 medium for most compounds, including
glycine. During incubations lasting three hours, the deleterious
effects of high calcium conditions on cytoprotection was more
strikingly shown, even for glycine. Values for LDH release from
cells exposed for three hours to injury conditions in high calcium
medium with 1 mM glycine and 1 m strychnine were 72 3 and
63 2 (N = 4), whereas the two compounds were completely
protective at the same concentrations in 100 nM Ca2 medium
(Fig. 1).
Discussion
Our studies show that several compounds which have activities
at diverse chloride channels, including amino acid gated chloride
channels, share cytoprotective actions in a well characterized
model of ATP depletion in MDCK cells. Beneficial effects of the
compounds were not mediated by improvement of energy status,
as demonstrated previously for glycine and related amino acids.
Use of the Ca2 clamping technique [9, 17] was required to
clearly characterize and compare cytoprotective activity. Benefi-
cial effects of glycine and other drugs were blunted, and in some
cases lost, when incubations were done in 1.25 mrvt Ca2 media.
This can be attributed to uncontrolled Ca2 influx through
ionomycin permeabilized membranes and ensuing Ca2 depen-
dent damage [10, 17]. Increased Caf can ultimately overwhelm
even the robust protection afforded by optimal concentrations (5
mM) of glycine [17]. For this reason, most studies reported here
were done in Ca2 clamped cells, where injury is completely
glycine dependent, and effects of the amino acid are fully ex-
pressed. In that many test compounds were less potent than
glycine, it became important to use Ca2 clamped cells to study
their specific actions also, free of non-specific damage caused by
increased Caf. Taken in this context, the striking benefits afforded
by glycine and other drugs with activity at chloride channels
suggest that the cytoprotective mechanisms of this heterogeneous
group of compounds may indeed be related. Our morphological
results are consistent with this notion in that the ultrastructure of
cells protected by diverse compounds was similar, with the
common feature of preserved plasma membrane integrity despite
considerable swelling of cells.
Cytoprotection appeared to be specific for chemical structure,
at least for some classes of compounds, and the benefits were
apparently not mediated by non-specific effects such as hydropho-
bic interactions. In proximal tubules, as well as in MDCK and
endothelial cells, amino acid cytoprotection is stringently depen-
dent on specific molecular features [3, 10, 28]. Structural speci-
ficity for the actions of amino acids could be shown even more
rigorously for MDCK cells injured under low calcium conditions
(unpublished observation). Comparison of chemical derivatives
showed structural requirements for the actions of avermectins
also (Table 2), arguing against non-specific stabilizing effects of
the compound on proteins or lipids as the explanation for their
cytoprotective activity. Similarly, TPMP, which has the same
triphenyl structure as cyanotriphenylboron [24], but is positively
charged, was inactive, whereas the negatively charged cyanotri-
phenylboron was protective. Brucine (2,3-dimethoxy-strychnine)
has been reported to be cytoprotective similar to strychnine [15],
but an examination of the structural requirements for the activity
of these alkaloids has not been possible owing to the lack of
availability of modified derivatives. Cytoprotection by other chlo-
ride channel blockers may also show structural specificity. Differ-
ent classes of these aromatic compounds share functionally im-
portant structural features and the property of negative charge
[27, 29]. DPC, NPPB and NIF are closely related arylaminoben-
zoates, but NPPB and NIF have higher binding affinities than
DPC to anion channels [29, 30]. In this regard, it is notable that
NPPB and NIF were more potent cytoprotectants than DPC.
Being somewhat different structurally, it is difficult to relate the
activity of IAA to the other three.
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Fig. 8. Electron microscopy of injured and protected MDCK cells incubated in 100 nii Ca2 medium containing ionomycin and CCCP without further
additions (a) or with 5 mMglycine (b) for three hours. The medium was formulated to replace chloride by gluconate. Cells with no further additions (a)
show an injury pattern that is indistinguishable from that seen in chloride medium (compare with Fig. 3b). On the other hand, there is notable absence
of cytoplasmic swelling and blebbing in the cell protected by glycine (Fig. 8b), compared to the corresponding cell protected by glycine in chloride
medium (Fig. 3c), although all organelles remain swollen nevertheless. Release of free LDH in the medium prior to fixation for EM was 95% from cells
with ionomycin and CCCP (I+C) alone (Fig. 8a), and 6% from cells with I+C and glycine (Fig. 8b). Magnifications are x5000 (a) and 6500 (b).
It was suggested that cytoprotection by glycine, strychnine and
certain chloride channel blockers is due to prevention of large
chloride fluxes through glycine receptor like proteins during
terminal phases of cell injury [14]. However, this hypothesis is
inconsistent with dissimilar effects of these drugs on chloride
transport. In our studies, replacement of medium chloride by
gluconate did not prevent membrane damage. Substantial glycine
preventable injury occured when chloride salts in media were
replaced by sucrose. These data show that lethal damage of
MDCK cells that was specifically preventable by glycine and other
drugs under our experimental conditions cannot be attributed to
chloride influx. Rather, they suggest that pathological membrane
pores must develop first in compromised cells, followed by
abnormal and irreversible transmembrane fluxes of solutes.
A notable feature of protected cells in gluconate media was
prevention of swelling and blebbing. This is consistent with the
concept that influx of chloride, accompanying that of sodium, and
followed by water, causes cell swelling when sodium pump
function is compromised [31J. Gluconate substitution may have
prevented cell swelling in the presence of glycine and other agents
because of osmotic effects across protected plasma membranes
impermeant to this large anion. On the other hand, failure by
gluconate to prevent swelling of cells in the absence of glycine or
other drugs is consistent with abnormal porosity of unprotected
plasma membranes. In this situation, large fluxes of gluconate
(and water) would be expected to occur after the membranes have
developed porous defects. Prevention of cell swelling is expected,
a priori, to decrease lethal cell damage and improve cell viability
[31—33]. However, such benefits were insubstantial under our
experimental conditions, and plasma membranes became abnor-
mally porous in spite of the presence of osmotically active agents
if glycine or other protective drugs were not also present. Viewed
in this context, our findings underscore the uniqueness of the
preservation of plasma membrane integrity by glycine, strychnine,
avermectin Bla, cyanotriphenylboron and other chloride channel
blockers. Their effects were not only of large magnitude, but
appeared to be similar to the extent that they were directed
towards at least one common structural locus in the cell (the
plasma membrane), and occurred under circumstances where the
deleterious effects of other factors contributing to cell injury such
as increases of Ca2 and cell swelling had been scrupulously
avoided.
Given that modification of energy metabolism or chloride
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Table 4. Cytoprotective effects in 1.25 ma Ca2 medium
Drug concentration mM Time
control0 0.1 0.5 1.0
GLY 92±2 87±1 54±6 22±2 2±1
STR 92±2 92±2 66±7 16±1 2±1
AVM 92±2 97±2 NT NT 2±1
CTB 91±4 58±5 16±2 3±0 2±0
IAA 95±2 89±3 27±4 17±2 1±0
NPP 95±2 74±6 17±5 4±2 1±0
DPC 95±2 94±3 90±5 77±6 1±0
NIF 95±2 88±4 69±6 68±12 1±0
Percent release of LDH from cells exposed to ionomycin and CCCP for
2 hours in KRB containing 1.25 m Cat (No added EGTA) without or
with 0.1 mM, 0.5 mM or 1.0 m glycine (GLY), strychnine (STR),
avermectin Bla (AVM), cyanotriphenylboron (CTB), indanyloxyacetic
acid (IAA), 5-nitro-2-(3-phenylpropylamino) benzoic acid (NPP), niflumic
acid (NIF) and from time controls without ionomycin and CCCP (N = 4).
NT, not tested because of drug insolubility.
transport cannot explain the protection afforded by diverse com-
pounds with known activities at chloride channels and chloride
channel receptors, hypotheses for their actions have to be specu-
lative at best. Although this cannot be proven at the present time,
the circumstances of injury and patterns of protection suggest to
us that the mechanisms of action may be related. The possibility
that these effects are due to non-specific "membrane stabilizing"
actions [34] appears unlikely, although rigorous structure activity
studies are needed to resolve this question. However, based on
known information regarding the interactions of glycine and other
agents with ion channels, we would like to offer a highly specula-
tive explanation for their cytoprotective effects. This is an exten-
sion of the hypothesis that the protective effects of glycine may be
mediated by interaction with proteins related in structure to
glycine receptors in the CNS.
Glycine receptors are hetero-oligomeric transmembrane pro-
teins, whose functions are regulated by protein conformation and
subunit interactions. Chloride channels, including those of glycine
receptors, are known to alternate between multiple conductance
states indicating frequent variations of channel size [35, 36]. Such
physiological regulation of channel structure may break down
during ATP depletion, and pathological pores develop, because of
proteolysis or altered phosphotylation of channel protein sub-
units. Receptor occupancy by the appropriate ligand could per-
haps preserve channel structure by maintaining protein confor-
mation and subunit interactions. It is of interest that mammalian
glycine and GABAA receptors and invertebrate glutamate gated
chloride channels (which are the targets of the avermectins) are
similar overall in their subunit and molecular structure, particu-
larly in the channel forming M2 domains [25, 37], and avermectin
Bla binds to, and is an agonist, not only at invertebrate glutamate
receptors, but also at mammalian chloride channel receptors
[20—23, 38, 39]. Bicuculline, which has activity at GABAA and
glycine receptors [13], was shown to protect ATP depleted
proximal tubules [12]. The binding of avermectin to the mamma-
lian brain receptor site is sensitive to medium chloride [23], and if
the hypothesis offered here for its cytoprotective activity is correct,
this may explain the weakening of the benefits of the compound in
gluconate medium.
Reservations regarding these interpretations are that the con-
centrations required for cytoprotection by some of the putative
ligands are excessive, relative to known affinities at chloride
channel receptors, and that at least one of the effects is aberrant.
For example, the Kd for strychnine at the adult-spinal cord glycine
receptor is < 10 n and strychnine is an antagonist of glycine,
whereas in the cytoprotective system, the actions of the alkaloid
are like that of glycine and require high concentrations. That the
analogy is not farfetched is suggested by the fact that there are
glycine receptor variants with much lower affinities for glycine and
strychnine within the CNS itself [40]. Subtle mutations of the
glycine receptor can drastically alter affinity constants and binding
properties [41].
The protective actions of chloride channel blockers cannot be
reconciled with a hypothesis based on ligand binding. However,
these agents bind to channel domains through hydrophobic and
ionic interactions, and it is theoretically possible that subunit
interactions in a putative multimeric channel protein may be
stabilized by such binding. In this context, cyanotriphenylboron
and nifiumic acid, which were the most protective chloride
channel blockers, are known to bind glycine receptor M2 channel
domains [24, 42].
It is not farfetched to consider that proteins related to neuro-
transmitter receptors may be found in non-neuronal, parenchymal
cells. Low affinity avermectin binding was detected in rat liver and
kidney [23], and recently, /3 subunits of GABAA receptors were
reported to be present in rat renal nephron segments [43]. The
strength of the hypothesis being presented here rests not on the
actions of one individual agent or a single family of drugs, but on
the remarkable cytoprotection offered by several families of
compounds, all of which have activity at a specific group of
ligand-gated chloride channel receptors. The involvement of
specific proteins of this type in cell injury will have to be
investigated in future work. The present studies provide substan-
tially expanded pharmacological tools and an improved model
system that will be important for this purpose.
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